Company Overview of Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc., a biopharmaceutical company, engineers drug conjugates that maximize the potential of new and established therapeutic classes. The company develops a portfolio of antibody-drug conjugates to improve patient outcomes in multiple oncology indications. Its clinical-stage product candidates include XMT-1001, a “tecan” conjugate for patients with lung cancers; and XMT-1107, an anti-angiogenic conjugate for patients with refractory, advanced solid tumors. The company’s conjugation system provides benefits for the development of drugs across therapeutic modalities, including antibody-drug conjugates, antibody fragments, small molecules, biologics, and synergistic drug co...
840 Memorial Drive
Cambridge, MA 02139
Founded in 2001
Key Executives for Mersana Therapeutics, Inc.
Vice President of Finance
Head of Clinical Development & Regulatory Affairs
Compensation as of Fiscal Year 2014.
Mersana Therapeutics, Inc. Key Developments
Merck and Mersana Collaborate to Develop Antibody-Drug Conjugates for Cancer
Jun 30 14
Merck Serono and Mersana Therapeutics, Inc. have collaborated to develop next-generation antibody-drug conjugates, or ADCs, for cancer. ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody part specifically targets and delivers the cytotoxic drug to cancer cells which could lead to higher drug levels at the tumor site. Mersana and Merck Serono will leverage Mersana's Fleximer technology to generate ADCs for multiple undisclosed targets. Both parties have agreed to test a variety of ADCs by utilizing Mersana's platform technologies and several cytotoxic agents as conjugates. This agreement further underlines Merck Serono's approach to employ a collaborative R&D model, creating strategic partnerships to drive innovation, being consciously agnostic of the source of potential novel assets, and technologies.
Mersana Therapeutics, Inc. and Merck KGaA Announce an Agreement to Develop Next-Generation Antibody-Drug Conjugates
Jun 24 14
Mersana Therapeutics, Inc. and the biopharmaceutical division of Merck KGaA announced an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs). ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody specifically targets and delivers the cytotoxic drug to cancer cells, which could lead to higher drug levels at the tumor site. Mersana and the biopharmaceutical division of Merck KGaA will leverage Mersana's Fleximer(R) technology to generate ADCs for multiple undisclosed targets. Both parties have agreed to test a variety of ADCs by utilizing Mersana's platform technologies and several cytotoxic agents as conjugates. Under the agreement, Merck KGaA will provide monoclonal antibodies to Mersana, which will generate the Fleximer-ADCs and conduct drug discovery and preclinical development activities. Merck KGaA will be responsible for clinical development and commercialization of any products under an exclusive license from Mersana. In addition to an upfront payment, Mersana is eligible to receive milestones plus royalties on worldwide net sales of products.
Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates
Apr 7 14
Mersana Therapeutics, Inc. announced that it has entered into a collaboration agreement with Millennium Pharmaceuticals, Inc. to develop next-generation, Fleximer(R) antibody-drug conjugates (ADCs). Mersana's proprietary conjugation technology is comprised of the company's biodegradable Fleximer polymer and a broad array of customizable linker chemistries matched to Mersana's diverse, cytotoxic payloads. Under the agreement, Takeda will provide an upfront payment to Mersana for the right to utilize Fleximer technology to develop novel ADC candidates. Mersana is responsible for conducting research and creating ADCs that are conjugates of Takeda's antibodies and Mersana's diverse payload platforms, which combine a cytotoxic payload with the Fleximer polymer and custom linkers. In addition to providing antibodies, Takeda is responsible for product development, manufacturing and commercialization of any Fleximer-ADC products. In addition to an upfront payment, Mersana is eligible to receive milestones and royalties on worldwide net sales of any resulting ADC products.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|